Esperion Therapeutics, Inc.
General ticker "ESPR" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $476.2M (TTM average)
Esperion Therapeutics, Inc. follows the US Stock Market performance with the rate: 49.8%.
Estimated limits based on current volatility of 0.4%: low 3.13$, high 3.14$
Factors to consider:
- Total employees count: 304 (+26.7%) as of 2024
- Top business risk factors: Dependence on two products, Regulatory and compliance, Senior management dependency, Liquidity and credit risks, Operational and conduct risks
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.42$, 6.23$]
- 2026-12-31 to 2027-12-31 estimated range: [1.75$, 4.68$]
Financial Metrics affecting the ESPR estimates:
- Positive: with PPE of -22.7 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Positive: 7.54 < Operating profit margin, % of 14.95
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0.13 <= 0.78
Short-term ESPR quotes
Long-term ESPR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $116.33MM | $332.31MM | $403.13MM |
| Operating Expenses | $271.90MM | $277.91MM | $342.86MM |
| Operating Income | $-155.56MM | $54.40MM | $60.27MM |
| Non-Operating Income | $-53.69MM | $-106.15MM | $-81.11MM |
| Interest Expense | $58.98MM | $59.25MM | $84.60MM |
| R&D Expense | $86.11MM | $46.24MM | $47.85MM |
| Income(Loss) | $-209.25MM | $-51.74MM | $-20.84MM |
| Taxes | $0.00MM | $0.00MM | $1.84MM |
| Net Income(Loss)* | $-209.25MM | $-51.74MM | $-22.68MM |
| Stockholders Equity | $-454.99MM | $-388.72MM | $-301.96MM |
| Inventory | $65.62MM | $94.49MM | $105.12MM |
| Assets | $205.80MM | $343.82MM | $465.89MM |
| Operating Cash Flow | $-135.49MM | $-23.65MM | $-13.09MM |
| Capital expenditure | $0.00MM | $0.32MM | $0.00MM |
| Investing Cash Flow | $42.50MM | $-0.32MM | $0.00MM |
| Financing Cash Flow | $50.46MM | $86.48MM | $36.18MM |
| Earnings Per Share** | $-2.03 | $-0.28 | $-0.11 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.